Drugs /

lu 177-psma-617

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.

Clinical Trials

View Clinical Trials for lu 177-psma-617

Lu 177-psma-617 has been investigated in 6 clinical trials, of which 5 are open and 1 is closed. Of the trials investigating lu 177-psma-617, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 3 (3 open).

FOLH1 Expression and FOLH1 Overexpression are the most frequent biomarker inclusion criteria for lu 177-psma-617 clinical trials.

Prostate adenocarcinoma and prostate carcinoma are the most common diseases being investigated in lu 177-psma-617 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lu 177-Psma-617
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lu 177-Psma-617
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lu 177-psma-617 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lu177-psma-617, 177lu-psma-617, lutetium lu 177-psma-617
Drug Target(s) [2]:
FOLH1
NCIT ID [1]:
C148145

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.